Characterization of Human Memory Immune Responses to Prior Yellow Fever Vaccination
NCT01244802 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2024-11-04
Summary
The objective of this study is to study immune memory generated against the yellow fever (YFV) vaccine in participants who have previously received the vaccine. Volunteers will not receive vaccine shots; only immune responses to previous yellow fever vaccination will be studied. The study involves one or multiple blood draws.
Conditions
- Yellow Fever Vaccine
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
Emory University
lead OTHER
Principal Investigators
-
Rafi Ahmed, PhD · Emory University
-
Srilatha Edupuganti, MD · Emory University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-11-30
- Primary Completion
- 2029-10-31
- Completion
- 2029-10-31
Countries
- United States
Study Locations
More Related Trials
-
PRIME Follow up - Quadri Meningo Vacinees
NCT02811120 ·Status: COMPLETED
-
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
NCT00262002 ·Status: COMPLETED ·Phase: PHASE2
-
Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults
NCT00772629 ·Status: TERMINATED ·Phase: PHASE2
-
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis
NCT01482052 ·Status: COMPLETED ·Phase: PHASE1
-
Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
NCT02285777 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)
NCT03964012 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose
NCT02514746 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
NCT01148017 ·Status: COMPLETED ·Phase: PHASE3
-
Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination
NCT04722003 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine
NCT04689191 ·Status: UNKNOWN ·Phase: PHASE3
-
Immunologic Responses to a Live Attenuated Oral Cholera Vaccine
NCT03251495 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults
NCT02810340 ·Status: COMPLETED ·Phase: PHASE1
-
Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine
NCT05093829 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49
NCT04142242 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612
NCT00955682 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)
NCT02451514 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
NCT02531698 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi
NCT03299426 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months
NCT05229536 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
NCT00772070 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old
NCT04714229 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine
NCT02639351 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months
NCT05252715 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Effect of Meningococcal Conjugate Vaccine on Meningococcal Carriage
NCT00119080 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612
NCT00974363 ·Status: COMPLETED ·Phase: PHASE3